selegiline has been researched along with tolcapone in 20 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 9 (45.00) | 18.2507 |
| 2000's | 7 (35.00) | 29.6817 |
| 2010's | 4 (20.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| Chupka, J; El-Kattan, A; Feng, B; Miller, HR; Obach, RS; Troutman, MD; Varma, MV | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Choi, SS; Contrera, JF; Hastings, KL; Kruhlak, NL; Sancilio, LF; Weaver, JL; Willard, JM | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Kaakkola, S; Wurtman, RJ | 1 |
| Burns, RS; Davis, TL; Roznoski, M | 2 |
| Ekblom, J; Garpenstrand, H; Oreland, L; Prince, JA; Tottmar, O | 1 |
| Dorflinger, EE; Hauser, RA; Molho, E; Pedder, S; Shale, H | 1 |
| Ekblom, J; Oreland, L; Tottmar, O | 1 |
| Kurlan, R; Siderowf, A | 1 |
| Stacy, M | 1 |
| Ahlskog, JE | 1 |
| Cullen, N; Lexell, J; Zafonte, RD | 1 |
| Foley, P; Gerlach, M; Riederer, P | 1 |
| Goetz, CG; Poewe, W; Rascol, O; Sampaio, C | 1 |
| Pirtosek, Z | 1 |
| Baqi, Y; Correa, M; Khan, B; Lee, CA; Makriyannis, A; Müller, CE; Nowak, V; Nunes, EJ; Pandit, S; Randall, PA; Salamone, JD; Shah, P; Vemuri, VK; Yohn, SE | 1 |
| Aschner, M; Bornhorst, J; Chakraborty, S; Gulbins, E; Kleuser, B; Schumacher, F; Schwerdtle, T | 1 |
7 review(s) available for selegiline and tolcapone
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Monoamine oxidase and catechol-O-methyltransferase inhibitors.
Topics: Benzophenones; Catechol O-Methyltransferase Inhibitors; Catechols; Dopamine; Enzyme Inhibitors; Humans; Monoamine Oxidase Inhibitors; Nitriles; Nitrophenols; Parkinson Disease; Randomized Controlled Trials as Topic; Selegiline; Tolcapone | 1999 |
Medical treatment of later-stage motor problems of Parkinson disease.
Topics: Amantadine; Antiparkinson Agents; Benzophenones; Carbidopa; Catechol O-Methyltransferase Inhibitors; Catechols; Cholinergic Antagonists; Dopamine Agonists; Dose-Response Relationship, Drug; Drug Combinations; Dyskinesia, Drug-Induced; Enzyme Inhibitors; Humans; Levodopa; Nitriles; Nitrophenols; Parkinson Disease, Secondary; Propranolol; Randomized Controlled Trials as Topic; Selegiline; Tolcapone | 1999 |
Possible applications for dopaminergic agents following traumatic brain injury: part 2.
Topics: Amantadine; Benzophenones; Benzothiazoles; Brain Injuries; Catechols; Dopamine Agents; Humans; Indoles; Neuroprotective Agents; Nitriles; Nitrophenols; Patient Selection; Pramipexole; Selegiline; Thiazoles; Tolcapone | 2001 |
The relevance of preclinical studies for the treatment of Parkinson's disease.
Topics: Antiparkinson Agents; Benzophenones; Drug Evaluation, Preclinical; Humans; Levodopa; Neuroprotective Agents; Nitrophenols; Parkinson Disease; Selegiline; Tolcapone | 2003 |
Evidence-based medical review update: pharmacological and surgical treatments of Parkinson's disease: 2001 to 2004.
Topics: Amantadine; Antiparkinson Agents; Apomorphine; Benzophenones; Benzothiazoles; Bromocriptine; Cabergoline; Catechol O-Methyltransferase Inhibitors; Deep Brain Stimulation; Dihydroergocryptine; Ergolines; Fetal Tissue Transplantation; Globus Pallidus; Humans; Indans; Indoles; Levodopa; Lisuride; Mesencephalon; Monoamine Oxidase Inhibitors; Neurosurgical Procedures; Nitrophenols; Parkinson Disease; Pergolide; Piribedil; Pramipexole; Selegiline; Thiazoles; Tolcapone | 2005 |
'Bad guys' among the antiparkinsonian drugs.
Topics: Antiparkinson Agents; Benzophenones; Cholinergic Antagonists; Cognition; Dopamine Agonists; Humans; Levodopa; Nitrophenols; Parkinson Disease; Randomized Controlled Trials as Topic; Selegiline; Survival Rate; Tolcapone; Treatment Outcome | 2009 |
3 trial(s) available for selegiline and tolcapone
| Article | Year |
|---|---|
Effects of tolcapone in Parkinson's patients taking L-dihydroxyphenylalanine/carbidopa and selegiline.
Topics: Aged; Antiparkinson Agents; Benzophenones; Carbidopa; Catechol O-Methyltransferase Inhibitors; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Female; Humans; Levodopa; Male; Middle Aged; Neurologic Examination; Nitrophenols; Parkinson Disease; Selegiline; Tolcapone | 1995 |
Acute effects of COMT inhibition on L-DOPA pharmacokinetics in patients treated with carbidopa and selegiline.
Topics: Aged; Antiparkinson Agents; Benzophenones; Carbidopa; Dose-Response Relationship, Drug; Humans; Levodopa; Movement Disorders; Nitrophenols; Parkinson Disease; Selegiline; Tolcapone | 1995 |
A pilot evaluation of the tolerability, safety, and efficacy of tolcapone alone and in combination with oral selegiline in untreated Parkinson's disease patients. Tolcapone De Novo Study Group.
Topics: Administration, Oral; Aged; Antiparkinson Agents; Benzophenones; Catechol O-Methyltransferase Inhibitors; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Neurologic Examination; Nitrophenols; Parkinson Disease; Pilot Projects; Selegiline; Tolcapone; Treatment Outcome | 1998 |
10 other study(ies) available for selegiline and tolcapone
| Article | Year |
|---|---|
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Physicochemical determinants of human renal clearance.
Topics: Humans; Hydrogen Bonding; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Kidney; Metabolic Clearance Rate; Molecular Weight | 2009 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
Topics: | 2008 |
Effects of COMT inhibitors on striatal dopamine metabolism: a microdialysis study.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Benzophenones; Catechol O-Methyltransferase Inhibitors; Catechols; Chromatography, High Pressure Liquid; Clorgyline; Corpus Striatum; Dialysis; Dopamine; Homovanillic Acid; Hydroxyindoleacetic Acid; Male; Nitriles; Nitrophenols; Nomifensine; Rats; Rats, Inbred Strains; Selegiline; Tolcapone | 1992 |
A cell culture model of cerebral ischemia as a convenient system to screen for neuroprotective drugs.
Topics: Animals; Benzophenones; Brain Ischemia; Catechol O-Methyltransferase Inhibitors; Cell Survival; Cells, Cultured; Embryo, Mammalian; Enzyme Inhibitors; L-Lactate Dehydrogenase; Models, Neurological; Monoamine Oxidase Inhibitors; Neurons; Neuroprotective Agents; Nitrophenols; Prosencephalon; Rats; Rats, Sprague-Dawley; Selegiline; Time Factors; Tolcapone | 1998 |
Cytoprotection by deprenyl and tolcapone in a cell culture model of cerebral ischaemia.
Topics: Animals; Benzophenones; Brain Ischemia; Catechol O-Methyltransferase; Catechol O-Methyltransferase Inhibitors; Cell Hypoxia; Cells, Cultured; Cytoprotection; Drug Combinations; Female; Hypoglycemia; In Situ Nick-End Labeling; L-Lactate Dehydrogenase; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Neuroprotective Agents; Nitrophenols; Pregnancy; Prosencephalon; Rats; Rats, Sprague-Dawley; Selegiline; Tolcapone | 1998 |
Parkinson's disease: therapeutic choices and timing decisions in patient management. Interview by Wayne Kuznar.
Topics: Age Factors; Aged; Antiparkinson Agents; Benzophenones; Carbidopa; Disease Progression; Drug Administration Schedule; Electric Stimulation Therapy; Humans; Levodopa; Middle Aged; Nitrophenols; Parkinson Disease; Patient Selection; Selegiline; Time Factors; Tolcapone | 1999 |
The VMAT-2 inhibitor tetrabenazine affects effort-related decision making in a progressive ratio/chow feeding choice task: reversal with antidepressant drugs.
Topics: Animals; Antidepressive Agents; Benzazepines; Benzophenones; Bupropion; Cannabinoid Receptor Antagonists; Choice Behavior; Depression; Dopamine Antagonists; Drug Evaluation, Preclinical; Feeding Behavior; Male; Nitrophenols; Pyrazoles; Rats, Sprague-Dawley; Salicylamides; Selegiline; Tetrabenazine; Tolcapone; Vesicular Monoamine Transport Proteins; Xanthines | 2014 |
Highly sensitive isotope-dilution liquid-chromatography-electrospray ionization-tandem-mass spectrometry approach to study the drug-mediated modulation of dopamine and serotonin levels in Caenorhabditis elegans.
Topics: Animals; Benzophenones; Caenorhabditis elegans; Catechol O-Methyltransferase Inhibitors; Chromatography, High Pressure Liquid; Deuterium; Dopamine; Limit of Detection; Monoamine Oxidase Inhibitors; Nitrophenols; Selegiline; Serotonin; Spectrometry, Mass, Electrospray Ionization; Tandem Mass Spectrometry; Time Factors; Tolcapone | 2015 |